Literature DB >> 3511382

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.

P J Dyck, J Daube, P O'Brien, A Pineda, P A Low, A J Windebank, C Swanson.   

Abstract

Plasma exchange has been reported to be efficacious in chronic inflammatory demyelinating polyradiculoneuropathy. We performed a prospective double-blind trial in which patients with static or worsening disease were randomly assigned to plasma exchange (n = 15) or to sham exchange (n = 14) for three weeks. After three weeks, we observed statistically significant differences in combined measurements of nerve conduction (total, motor, proximal, velocity, and amplitude) favoring patients who had received plasma exchange. Improvement to a greater degree than for any patient receiving sham exchange was detected in the neurologic-disability score in five patients (P = 0.025) and in subset scores for weakness and reflex in four patients (P less than 0.057). We conclude that for some patients with chronic inflammatory demyelinating polyradiculoneuropathy, plasma exchange has an ameliorating effect on neurologic dysfunction and nerve conduction, but in others no improvement is observed. Because plasma was replaced with normal serum albumin, a humoral factor or factors may have a role in the neurologic deficit of this disorder.

Entities:  

Mesh:

Year:  1986        PMID: 3511382     DOI: 10.1056/NEJM198602203140801

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  74 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 4.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

Review 5.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 7.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

8.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments.

Authors:  R Nemni; S Amadio; R Fazio; G Galardi; S Previtali; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 9.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 10.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.